DNA vaccines for cancer

Frontiers in Bioscience

Volumn 11, Issue 1 P.889-1198, 2006, Pages 1189-1198

  Shaw, Denise R ^a   Strong, Theresa V ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cancer Immunotherapy; DNA vaccine; Genetic Vaccines; Neoplasia; Plasmid Immunization; Review; Therapeutics; Treatment; Tumor

Indexed keywords

EID: 32844462026     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1872     Document Type: Review

References (96)

1. Rosenberg S. A., Y. Zhai, J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, C. A. Seipp, J. H. Einhorn, B. Roberts & D. E. White: Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90, 1894-1900 (1998)
2. Corny R. M., M. B. Khazaeli, M. N. Saleh, K. O. Allen, D. L. Barlow, S. E. Moore, D. Craig, R. B. Arani, J. Schlom & A. F. LoBuglio: Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 5, 2330-2337 (1999)
3. Dunn G. P., A. T. Brace, H. Ikeda, L. J. Old & R. D. Schreiber: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3, 991-998 (2002)
4. Wolff J. A, R. W. Malone, P. Williams, W. Chong, G. Acsadi, A. Jani & P. L. Feigner: Direct gene transfer into mouse muscle in vivo. Science 247, 1465-1468 (1990)
5. Hansen E., K. Fernandes, G. Goldspink, P. Butterworth, P. K. Umeda & K. C. Chang: Strong expression of foreign genes following direct injection into fish muscle. FEBS Lett 290, 73-76 (1991)
6. Jiao S., P. Williams, R. K. Berg, B. A. Hodgeman, L. Liu, G. Repetto & J. A. Wolff: Direct gene transfer into nonhuman primate myofibers in vivo. Hum Gene Ther 3, 21-33 (1992)
7. Danko I. & J. A. Wolff: Direct gene transfer into muscle. Vaccine 12, 1499-1502 (1994)
8. Wolff J. A., M. E. Dowry, S. Jiao, G. Repetto, R. K. Berg, J. J. Ludtke, P. Williams & D. B. Slautterback: Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle. J Cell Sci 103, 1249-1259 (1992)
9. Wolff J. A., J. J. Ludtke, G. Acsadi, P. Williams & A. Jani: Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1, 363-369 (1992)
10. Ulmer J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Feigner, V. J. Dwarki, S. H. Gromkowski, R. R. Deck, C. M. DeWitt, A. Friedman, L. A. Hawe, K. R. Leander, D. Martinez, H. C. Perry, J. W. Shiver, D. L. Montgomery & M. A. Liu: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745-1749 (1993)
11. Tang D. C., M. DeVit & S. A. Johnston: Genetic immunization is a simple method for eliciting an immune response. Nature 356, 152-154 (1992)
12. Williams R. S., S. A. Johnston, M. Riedy, M. J. De Vit, S. G. McElligott, & J. C. Sanford: Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc Natl Acad Sci USA 88, 2726-2730 (1991)
13. Barry M. A. & S. A. Johnston: Biological features of genetic immunization. Vaccine 15, 788-1791 (1997)
14. Fynan E. F., R. G. Webster, D. H. Fuller, J. R. Haynes, J. C. Santoro & H. L. Robinson: DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 90, 11478-11482 (1993)
15. Ross H. M., L. W. Weber, S. Wang, G. Piskun, R. Dyall, P. Song, Y. Takechi, J. Nikolic-Zugic, A. N. Houghton & J. J. Lewis: Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin Cancer Res 3, 2191-2196 (1997)
16. Cui Z., L. Baizer & R. J. Mumper: Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. J Biotechnol 102, 105-115 (2003)
17. Eriksson K. & J. Holmgren: Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14, 666-672 (2002)
18. Rocha-Zavaleta L., J. E. Alejandre & A. Garcia-Carranca: Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. J Med Virol 66, 86-95 (2002)
19. White S. A., A. F. LoBuglio, R. B. Arani, J. F. Pike, S. E. Moore, D. L. Barlow & R. M. Conry: Induction of antitumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine. J Gene Med 2, 135-140 (2000)
20. Pertmer T. M., T. R. Roberts & J. R. Haynes: Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol 70, 6119-6125 (1996)
21. Feltquate D. M., S. Heaney, R. G. Webster & H. L. Robinson: Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 158, 2278-2284 (1997)
22. Doe B., M. Selby, S. Barnett, J. Baenziger & C. M. Walker: Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci USA 93, 8578-8583 (1996)
23. Iwasaki A., C. A. Torres, P. S. Ohashi, H. L. Robinson & B. H. Barber: The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J Immunol 159, 11-14 (1997)
24. Fu T. M., J. B. Ulmer, M. J. Caulfield, R. R. Deck, A. Friedman, S. Wang, X. Liu, J. J. Donnelly & M. A. Liu: Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 3, 362-371 (1997)
25. Corr M., A. von Damm, D. J. Lee & H. Tighe: In vivo priming by DNA injection occurs predominantly by antigen transfer. J Immunol 163, 4721-4727 (1999)
26. Condon C., S. C. Watkins, C. M. Celluzzi, K. Thompson & L. D. Falo, Jr.: DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2, 1122-1128 (1996)
27. Casares S., K. Inaba, T. D. Brumeanu, R. M. Steinman & C. A. Bona: Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med 186, 1481-1486 (1997)
28. Song K., Y. Chang & G. J. Prud'homme: IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice. Gene Ther 7, 1527-1535 (2000)
29. Dranoff G: Coordinated tumor immunity. J Clin Invest 111, 1116-1118 (2003)
30. Curcio C., E. Di Carlo, R. Clynes, M. J. Smyth, K. Boggio, E. Quaglino, M. Spadaro, M. P. Colombo, A. Amici, P. L. Lollini, P. Musiani & G. Forni: Nonredundant roles of antibody, cytokines, and perform in the eradication of established Her-2/neu carcinomas. J Clin Invest 111, 1161-1170 (2003)
31. Klinman D. M., A. K. Yi, S. L. Beaucage, J. Conover & A. M. Krieg: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 93, 2879-2883 (1996)
32. Ashkar A. A. & K. L. Rosenthal: Toll-like receptor 9, CpG DNA and innate immunity. Curr Mol Med 2, 545-556 (2002)
33. Agrawal S. & E. R. Kandimalla: Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med 8, 114-121 (2002)
34. Dalpke A., S. Zimmermann & K. Heeg: Immunopharmacology of CpG DNA. Biol Chem 383, 1491-1500 (2002)
35. Davila E., M. G. Velez, C. J. Heppelmann & E. Celis: Creating space: an antigen-independent, CpG-induced peripheral expansion of naïve and memory T lymphocytes in a full T-cell compartment. Blood 100, 2537-2545 (2002)
36. Zinckgraf J. W. & L. K. Silbart: Modulating gene expression using DNA vaccines with different 3′-UTRs influences antibody titer, seroconversion and cytokine profiles. Vaccine 21, 1640-1649 (2003)
37. Xin K. Q., T. Ooki, N. Jounai, H. Mizukami, K. Hamajima, Y. Kojima, K. Ohba, Y. Toda, S. Hirai, D. M. Klinman, K. Ozawa & K. Okuda: A DNA vaccine containing inverted terminal repeats from adeno-associated virus increases immunity to HIV. J Gene Med 5, 438-445 (2003)
38. Hanke T., V. C. Neumann, T. J. Blanchard, P. Sweeney, A. V. Hill, G. L. Smith & A. McMichael: Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17, 589-596 (1999)
39. Smith B. F., H. J. Baker, D. T. Curiel, W. Jiang & R. M. Conry: Humoral and cellular immune responses of dogs immunized with a nucleic acid vaccine encoding human carcinoembryonic antigen. Gene Ther 5, 865-868 (1998)
40. Ito K., K. Ito, N. Shinohara & S. Kato: (2003) DNA immunization via intramuscular and intradermal routes using a gene gun provides different magnitudes and durations on immune response. Mol Immunol 39, 847-854 (2003)
41. Tuting T., A. Gambotto, P. D. Robbins, W. J. Storkus & A. B. DeLeo: Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther 6, 629-636 (1999)
42. Leitner W. W., M. C. Seguin, W. R. Ballou, J. P. Seitz, A. M. Schultz, M. J. Sheehy & J. A. Lyon: Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J Immunol 159, 6112-6119 (1997)
43. Gregoriadis G., A. Bacon, W. Caparros-Wanderley & B. McCormack: A role for liposomes in genetic vaccination. Vaccine 20, Suppl 5:B1-9 (2002)
44. Singh M., M. Briones, G. Ott & D. O'Hagan: Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 97, 811-816 (2000)
45. Drabick J. J., J. Glasspool-Malone, A. King & R. W. Malone: Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther 3, 249-255 (2001)
46. Paster W., M. Zehetner, M. Kalat, S. Schuller & T. Schweighoffer: In vivo plasmid DNA electroporation generates exceptionally high levels of epitope-specific CD8+ T-cell responses. Gene Ther 10, 717-724 (2003)
47. Chen H.-W., Y.-P. Lee, Y.-F. Chung, Y.C. Shih, J.-P Tsai, M.-H. Tao, & C.-C Ting. Inducing long-term survival with lasting anti-tumor immunity in treating B-cell lymphoma by a combined cell-based and hydrodynamic plasmid-encoding IL-12 gene therapy. Internal Immunol 15:427-435 (2003)
48. Hung C. F. & T. C. Wu: Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther 5, 20-24 (2003)
49. Xiang R., F. J. Primus, J. M. Ruehlmann, A. G. Niethammer, S. Silletti, H. N. Lode, C. S. Dolman, S. D. Gillies & R. A. Reisfeld: A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol 167, 4560-4565 (2001)
50. Hung C. F., K. F. Hsu, W. F. Cheng, C. Y. Chai, L. He, M. Ling & T. C. Wu: Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res 61, 1080-1088 (2001)
51. Boyle J. S., J. L. Brady & A. M. Lew: Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 392, 408-411 (1998)
52. Su Z., J. Vieweg, A. Z. Weizer, P. Dahm, D. Yancey, V. Turaga, J. Higgins, D. Boczkowski, E. Gilboa & J. Dannull: Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 62, 5041-5048 (2002)
53. Ji H., T. L. Wang, C. H. Chen, S. I. Pai, C. F. Hung, K. Y. Lin, R. J. Kurman, D. M. Pardoll & T. C. Wu: Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther 10, 2727-2740 (1999)
54. Xiang R., H. N. Lode, T. H. Chao, J. M. Ruehlmann, C. S. Dolman, F. Rodriguez, J. L. Whitton, W. W. Overwijk, N. P. Restifo & R. A. Reisfeld: An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci USA 97, 5492-5497 (2000)
55. Rice J., S. Buchan & F. K. Stevenson: Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. J Immunol 169, 3908-3918 (2002)
56. Cid-Arregui A., V. Juarez & H. zur Hausen: A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J Virol 77, 4928-4937 (2003)
57. Scheerlinck J. P., G. Casey, P. McWaters, J. Kelly, D. Woollard, M. W. Lightowlers, J. M. Tennent & P. J. Chaplin: The immune response to a DNA vaccine can be modulated by co-delivery of cytokine genes using a DNA prime-protein boost strategy. Vaccine 19, 4053-60 (2001)
58. Conry R. M., G. Widera, A. F. LoBuglio, J. T. Fuller, S. E. Moore, D. L. Barlow, J. Turner, N. S. Yang & D. T. Curiel: Selected strategies to augment polynucleotide immunization. Gene Ther 3, 67-74 (1996)
59. Irvine K. R., J. B. Rao, S. A. Rosenberg & N. P. Restifo: Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156, 238-245 (1996)
60. Kim J. J., J. S. Yang, K. Dang, K.H. Manson, & D. B. Weiner. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine adjuvants. Clin Cancer Res 7:882s-889s (2001)
61. Biragyn A., M. Surenhu, D. Yang, P. A. Ruffini, B. A. Haines, E. Klyushnenkova, J. J. Oppenheim & L. W. Kwak: Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 167, 6644-6653 (2001)
62. Kim J. J., J. S. Yang, T. Dentchev, K. Dang & D. B. Weiner: Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J Interferon Cytokine Res 20, 487-498 (2000)
63. Kim T. W., C. F. Hung, M. Ling, J. Juang, L. He, J. M. Hardwick, S. Kumar and T. C. Wu: Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 112, 109-117 (2003)
64. Cappello P., F. Triebel, M. Iezzi, C. Caorsi, E. Quaglino, P. L. Lollini, A. Amici, E. Di Carlo, P. Musiani, M. Giovarelli & G. Forni: LAG-3 Enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c Mice. Cancer Res 63, 2518-25 (2003)
65. He Y., A. A. Pimenov, J. V. Nayak, J. Plowey, L. D. Falo, Jr. & L. Huang: Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum Gene Ther 11, 547-554 (2002)
66. Fong C. L. & K. M. Hui: Generation of potent and specific cellular immune responses via in vivo stimulation of dendritic cells by pNGVL3-hFLex plasmid DNA and immunogenic peptides. Gene Ther 9, 1127-1138 (2002)
67. Weber L. W., W. B. Bowne, J. D. Wolchok, R. Srinivasan, J. Qin, Y. Moroi, R. Clynes, P. Song, J. J. Lewis & A. N. Houghton: Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 102, 1258-1264 (1998)
68. Su J. M., Y. Q. Wei, L. Tian, X. Zhao, L. Yang, Q. M. He, Y. Wang, Y. Lu, Y. Wu, F. Liu, J. Y. Liu, J. L. Yang, Y. Y. Lou, B. Hu, T. Niu, Y. J. Wen, F. Xiao, H. X. Deng, J. Li & B. Kan: Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res 63, 600-607 (2003)
69. Hawkins W. G., J. S. Gold, N. E. Blachere, W. B. Bowne, A. Hoos, J. J. Lewis & A. N. Houghton: Xenogeneic DNA immunization in melanoma models for minimal residual disease. J Surg Res 102, 137-143 (2002)
70. Bergman P. J., J. McKnight, A. Novosad, S. Charney, J. Farrelly, D. Craft, M. Wulderk, Y. Jeffers, M. Sadelain, A. E. Hohenhaus, N. Segal, P. Gregor, M. Engelhorn, I. Riviere, A. N. Houghton & J. D. Wolchok: Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 9, 1284-1290 (2003)
71. Wei Y.-Q., M.-J. Huang, L. Yang, X. Zhao, L. Tian, Y. Lu, J.- M. Shu, C.-J. Lu, T. Niu, B. Kang, Y.-Q. Mao, F. Liu, Y.-J. Wen, S. Lei, F. Luo, L.-Q. Zhou, F. Peng, Y. Jiang, J.-Y. Liu, H. Zhou, Q.-R. Wang, Q.-M. He, F. Xiao, Y.-Y. Lou, X.-J. Xie, Q. Li, Y. Wu, Z.-Y. Ding, B. Hu, M. Hu & W. Zhang: Immunogene therapy of tumors with vaccine based upon Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 98, 11545-11550 (2001)
72. Fong L., D. Brockstedt, C. Benike, J. K. Breen, G. Strang, C. L. Ruegg & E. G. Engleman: Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167, 7150-7156 (2001)
73. Woodberry T., J. Gardner, S. L. Elliott, S. Leyrer, D. M. Purdie, P. Chaplin & A. Suhrbier: Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias. J Immunol 170, 2599-2604 (2003)
74. Pasquini S., S. Peralta, E. Missiaglia, L. Carta & N. R. Lemoine: Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia. Gene Ther 9, 503-510 (2002)
75. Otten G., M. Schaefer, C. Greer, M. Calderon-Cacia, D. Coit, J. Kazzaz, A. Medina-Selby, M. Selby, M. Singh, M. Ugozzoli, J. Zur Megede, S. W. Barnett, D. O'Hagan, J. Donnelly & J. Ulmer: Induction of broad and potent antihuman immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles. J Virol 77, 6087-6092 (2003)
76. Wang R., D. L. Doolan, T. P. Le, R. C. Hedstrom, K. M. Coonan, Y. Charoenvit, T. R. Jones, P. Hobart, M. Margalith, J. Ng, W. R. Weiss, M. Sedegah, C. de Taisne, J. A. Norman, & S. L. Hoffman: Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 28, 476-480 (1998)
77. Roy M. J., M. S. Wu, L. J. Barr, J. T. Fuller, L. G. Tussey, S. Speller, J. CuIp, J. K. Burkholder, W. F. Swain, R. M. Dixon, G. Widera, R. Vessey, A. King, G. Ogg, A. Gallimore, J. R. Haynes & D. Heydenburg Fuller: Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19, 764-778 (2000)
78. MacGregor R. R., R. Ginsberg, K. E. Ugen, Y. Baine, C. U. Kang, X. M. Tu, T. Higgins, D. B. Weiner & J. D. Boyer: T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 envandrev. AIDS 16, 2137-2143 (2002)
79. Calarota S., G. Bratt, S. Nordlund, J. Hinkula, A. C. Leandersson, E. Sandstrom & B. Wahren: Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351, 1320-1325 (1998)
80. Conry R. M., D. T. Curiel, T. V. Strong, S. E. Moore, K. O. Allen, D. L. Barlow, D. R. Shaw & A. F. LoBuglio: Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 8, 2782-2787 (2002)
81. Rosenberg S. A., J. C. Yang, R. M. Sherry, P. Hwu, S. Topalian, D. J. Schwartzentraber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, K. E. Morton, S. A. Mavroukakis & D. E. White: Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 14, 709-714 (2003)
82. Tagawa S. T., P. Lee, J. Snively, W. Boswell, S. Ounpraseuth, S. Lee, B. Hickingbottom, J. Smith, D. Johnson, & J.S. Weber. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 98, 144-154 (2003)
83. Pavlenko, M., A. K. Ross, A. Lundqvist, A. Palmborg, A.M. Miller, V. Ozenci, B. Bergman, L. Egevad, M. Hellstrom, R. Kiessling, G. Masucci, P. Wersall, S. Nilsson, & P. Pisa. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91, 688-694 (2004)
84. Timmerman J. M., G. Singh, G. Hermanson, P. Hobart, D. K. Czerwinski, B. Taidi, R. Rajapaksa, C. B. Caspar, A. Van Beckhoven & R. Levy: Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 62, 5845-5852 (2002)
85. Timmerman J. M. & R. Levy: The history of the development of vaccines for the treatment of lymphoma. Clin Lymphoma 1, 129-139 (2000)
86. Bendandi M., C. D. Gocke, C. B. Kobrin, F. A. Benko, L. A. Sternas, R. Pennington, T. M. Watson, C. W. Reynolds, B. L. Gause, P. L. Duffey, E. S. Jaffe, S. P. Creekmore, D. L. Longo & L. W. Kwak: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5, 1171-1177 (1999)
87. Klencke B., M. Matijevic, R. G. Urban, J. L. Lathey, M. L. Hedley, M. Berry, J. Thatcher, V. Weinberg, J. Wilson, T. Darragh, N. Jay, M. Da Costa & J. M. Palefsky: Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 8, 1028-1037 (2002)
88. Sheets E. E., R. G. Urban, C. P. Crum, M. L. Medley, J. A. Politch, M. A. Gold, L. I. Muderspach, G. A. Cole & P. A. Crowley-Nowick: Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 188, 916-926 (2003)
89. Stevanovic S.: Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2, 514-520 (2002)
90. Nelson P. S.: Identifying immunotherapeutic targets for prostate carcinoma through the analysis of gene expression profiles. Ann NY Acad Sci 975, 232-46 (2002)
91. Schultze J. L. & R. H. Vonderheide: From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol 22, 516-523 (2001)
92. Chen Y. T.: Cancer vaccine: identification of human tumor antigens by SEREX. Cancer J 6, Suppl 3, S208-217 (2000)
93. Naour F. L., F. Brichory, L. Beretta & S. M. Hanash: Identification of tumor-associated antigens using proteomics. Technol Cancer Res Treat 1, 257-262 (2002)
94. Niethammer A. G., R. Xiang, J. C. Becker, H. Wodrich, U. Pertl, G. Karsten, B. P. Eliceiri & R. A. Reisfeld: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8, 1369-1375 (2002)
95. Xiang R., N. Mizutani, Y. Lou, C. Chiodoni, H. Zhou, M. Mizutani, Y. Ba, J.C. Becker, & R. A. Reisfeld: A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 65, 553-561, (2005)
96. McConkey S. J., W. H. Reece, V. S. Moorthy, D. Webster, S. Dunachie, G. Butcher, J. M. Vuola, T. J. Blanchard, P. Gothard, K. Watkins, C. M. Hannan, S. Everaere, K. Brown, K. E. Kester, J. Cummings, J. Williams, D. G. Heppner, A. Pathan, K. Flanagan, N. Arulanantham, M. T. Roberts, M. Roy, G. L. Smith, J. Schneider, T. Peto, R. E. Sinden, S. C. Gilbert & A. V. Hill: Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9, 729-735 (2003)